Viral Vaccine For Porcine Species (e.g., Swine, Etc.) Patents (Class 424/815)
-
Patent number: 8021670Abstract: The present invention relates to the use of an immunogenic dose of immunogenic material of Mycoplasma hyopneumoniae and an immunogenic dose of live attenuated PRRS virus for the manufacture of a vaccine, and to a vaccine kit comprising such a vaccine.Type: GrantFiled: April 6, 2007Date of Patent: September 20, 2011Assignee: Intervet International B.V.Inventors: Christa Sibilla Drexler, Maarten Witvliet
-
Patent number: 6660262Abstract: A new and improved formulation and method for making same, for a broad spectrum antimicrobial treatment for bacterial and viral infections in cattle, horses, pigs, sheep and other domestic and non-domestic animals. More particularly, the present invention relates to a treatment which enables rapid relief of symptoms in an affected animal with a mortality of less than 1 percent by providing trace organic minerals in microgram quantities which act as nutrients for the animal. The treatment provides further nutritional requirements in the form of vitamin A, folic acid and vitamin D3 supplements, cobalt amino acid chelates and dried kelp, a source of minerals, amino acids, simple and complex carbohydrates, iodine and fiber. In addition, a bacterial innoculum consisting of Acidophilus species is introduced which would inhibit growth of pathogenic or opportunistic species of bacteria by competition for nutrients as well as providing for required vitamins as a by-product of metabolism.Type: GrantFiled: September 28, 2001Date of Patent: December 9, 2003Assignee: Bovine Health Products, Inc.Inventor: Randy R. McKinney
-
Patent number: 6641819Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation. The present invention also provides diagnostic testing methods which can differentiate between animals infected with field strains and attenuated strains of PRRSV.Type: GrantFiled: October 18, 2001Date of Patent: November 4, 2003Assignees: USDA, Boehringer Ingelheim Corp.Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Kelly Burkhart, David E. Gorcyca, Mike Roof
-
Patent number: 6616929Abstract: The invention relates to nucleic acids containing a nucleotide sequence encoding a polypeptide, the polypeptide having (1) the P2 and P3 regions of a swine vesicular disease virus polyprotein, and (2) an amino acid sequence heterologous to the polyprotein. The invention also includes methods of preparing such nucleic acids (e.g., RNA or DNA expression vectors) and methods of using such nucleic acids to express RNA or protein.Type: GrantFiled: October 6, 2000Date of Patent: September 9, 2003Assignee: Development Center for BiotechnologyInventors: Ching-Long Hwong, Cheng-Kai Lo, Lung-Shen Lin, Li-Yen Edward Chang
-
Publication number: 20030118608Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: ApplicationFiled: August 21, 2002Publication date: June 26, 2003Inventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol, Robertus Jacobus Maria Moormann, Johanna Jacoba Maria Meulenberg
-
Patent number: 6576243Abstract: Disclosed and claimed is: an immunogenic or vaccine composition for inducing in an avian host an immunological response against avian pathologies containing at least one plasmid that contains and expresses in vivo in an avian host cell nucleic acid molecule(s) having sequence(s) encoding antigen(s) of the avian pathogen(s); and, methods for using and kits employing such compositions.Type: GrantFiled: February 16, 2001Date of Patent: June 10, 2003Assignee: MerialInventors: Jean-Christophe Audonnet, Annabelle Bouchardon, Philippe Baudu, Michel Riviere
-
Publication number: 20030072771Abstract: Substantially avirulent forms of atypical porcine reproductive and respiratory syndrome (PRRS) virus and corresponding vaccines are provided which result from cell culture passaging of virulent forms of PRRS. The resultant avirulent atypical PRRS virus is useful as a vaccine in that PRRS specific antibody response is elicited by inoculation of host animals, thereby conferring effective immunity against both previously known strains of PRRS virus and newly isolated atypical PRRS virus strains. The preferred passaging technique ensures that the virus remains in a logarithmic growth phase substantially throughout the process, which minimizes the time required to achieve attenuation.Type: ApplicationFiled: May 9, 2002Publication date: April 17, 2003Inventors: William L. Mengeling, Ann Vorwald, Kelly Lager, Mike Roof, Kelly Burkhart, David E. Gorcyca
-
Publication number: 20020172690Abstract: The invention provides isolated polynucleotide molecules, including plasmids; viral vectors; and transfected host cells that comprise a DNA sequence encoding an infectious RNA sequence encoding a North American PRRS virus; and also North American PRRS viruses encoded thereby. The invention further provides isolated infectious RNA molecules encoding a North American PRRS virus. The invention also provides isolated polynucleotide molecules, infectious RNA molecules, viral vectors, and transfected host cells encoding genetically-modified North American PRRS viruses; and genetically-modified North American PRRS viruses encoded thereby. The invention also provides vaccines comprising such plasmids, RNA molecules, viral vectors, and North American PRRS viruses, and methods of using these vaccines in swine and in other animals. Also provided are isolated polynucleotide molecules, viral vectors, and transfected host cells that comprise a nucleotide sequence encoding a peptide of a North American PRRS virus.Type: ApplicationFiled: April 22, 2002Publication date: November 21, 2002Inventors: Jay G. Calvert, Michael G. Sheppard, Siao-Kun W. Welch
-
Publication number: 20020146431Abstract: The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.Type: ApplicationFiled: February 16, 2001Publication date: October 10, 2002Inventors: Gordon Moore Allan, Brian Martin Meehan, John Albert Ellis, George Steven Krakowka, Jean-Christophe Francis Audonnet
-
Publication number: 20020098573Abstract: An infectious clone based on the genome of a wild-type RNA virus is produced by the process of providing a host cell not susceptible to infection by the wild-type RNA virus, providing a recombinant nucleic acid based on the genome of the wild-type RNA virus, transfecting the host cell with the recombinant nucleic acid and selecting for infectious clones. The recombinant nucleic acid comprises at least one full-length DNA copy or in vitro-transcribed RNA copy or a derivative of either. The infectious clones can be used in single or dual purpose vaccines and in viral vector vaccines.Type: ApplicationFiled: June 5, 2001Publication date: July 25, 2002Inventors: Johanna Jacoba Maria Meulenberg, Johannes Maria Antonius Pol, Judy Norma Aletta Bos-de Ruijter
-
Patent number: 6251404Abstract: The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and/or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and/or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and/or infectious agent which causes a porcine respiratory and reproductive disease.Type: GrantFiled: May 13, 1997Date of Patent: June 26, 2001Assignees: Iowa State University Research Foundation, Solvay Animal Health, Inc.Inventors: Prem S. Paul, Patrick G. Halbur, Xiang-Jin Meng, Young S. Lyoo, Melissa Anne Lum
-
Patent number: 6217883Abstract: The invention relates to antigenic preparations and vaccines directed against the porcine multisystemic wasting syndrome (PMWS), comprising at least one porcine circovirus antigen, preferably type II, and at least one porcine parvovirus antigen.Type: GrantFiled: July 1, 1999Date of Patent: April 17, 2001Assignees: Merial, The Queen's University of Belfast, University of SaskatchewanInventors: Gordon Moore Allan, Brian Martin Meehan, John Albert Ellis, George Steven Krakowka, Jean-ChrJistophe Francis Audonnet
-
Patent number: 6200576Abstract: The present invention relates to a gene of swine vesicular disease virus (SVDV) and the mutant strains of the gene, and the expression plasmids, the preparation process thereof. The invention also relates to a vaccine for use in the prophylaxis of swine vesicular disease composition containing the mutant strains. Furthermore, the invention provides a process for differentiating mutant strains of SVDV from the wild type strain of SVDV, coxsackievirus and foot-and-mouth disease virus by polymerase chain reaction.Type: GrantFiled: July 15, 1998Date of Patent: March 13, 2001Assignee: Development Center for BiotechnologyInventors: Ching Long Hwong, Cheng-Kai Lo, Ying-Chuan Yang, King-Song Jeng, Edward L. Chang
-
Patent number: 6197310Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: GrantFiled: November 13, 1996Date of Patent: March 6, 2001Assignee: Stichting Centraal Diergeneeskundig InstituutInventors: Gert Wensvoort, Catharinus Terpstra, Joannes Maria Anthonis Pol
-
Patent number: 6110467Abstract: The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and/or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and/or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and/or infectious agent which causes a porcine respiratory and reproductive disease.Type: GrantFiled: May 13, 1997Date of Patent: August 29, 2000Assignees: Iowa State University Research Foundation, Solvay Animal Health, Inc.Inventors: Prem S. Paul, Patrick G. Halbur, Xiang-Jin Meng, Young S. Lyoo, Melissa Anne Lum
-
Patent number: 6080570Abstract: The invention includes a vaccine and sera for treatment of Mystery Swine Disease (MSD), a method for producing the vaccine, methods for diagnosis of MSD, a viral agent that will mimic "mystery swine disease" and antibodies to the viral agent useful in diagnosis and treatment of MSD. The serum contains mammalian antibodies which are effective in treating MSD.Type: GrantFiled: September 10, 1997Date of Patent: June 27, 2000Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Danny W. Chladek, Louis L. Harris, David E. Gorcyca
-
Patent number: 6042830Abstract: A substantially avirulent vaccine against Porcine Reproductive and Respiratory Syndrome (PRRS) is provided, which effectively immunizes swine against the U.S. and European forms of the disease, together with a method of growing the viral agent in vitro, and a method of attenuating the virus for vaccine preparation.Type: GrantFiled: May 15, 1995Date of Patent: March 28, 2000Assignee: Boehringer Ingelheim Vetmedica, Inc.Inventors: Danny W. Chladek, David E. Gorcyca, Louis L. Harris
-
Patent number: 6001370Abstract: A new attenuated strain (CNCM Institut Pasteur I-1642) of the virus causing the swine disease known as porcine reproductive and respiratory syndrome (PRRS) is described, along with an attenuation and replication procedure of the same by using a new clone obtained from MA-104 monkey kidney cells (CNCM Institut Pasteur I-1643). Because of the innocuousness on swine and the high immunogenic activity, the said new attenuated strain allows the obtaining of vaccines and diagnostic kits which make possible both the early diagnosis of PRRS and an efficient preventive treatment of such disease.Type: GrantFiled: November 24, 1997Date of Patent: December 14, 1999Assignee: Laboratorios Hippra, S.A.Inventors: Reina Alemany Burch, Enric Espuna Maso, Pere Riera Pujadas, Narcis Saubi Roca
-
Patent number: 5976537Abstract: Vaccines against porcine reproductive and respiratory syndrome (PRRS) have been produced by attenuation of wild type strains of the virus selected from the group of attenuated NADC-8, attenuated NADC-9 and attenuated NVSL-14. These vaccines are useful in monovalent, bivalent or polyvalent vaccines.Type: GrantFiled: July 2, 1996Date of Patent: November 2, 1999Assignee: The United States of America as represented by the Secretary of AgricultureInventors: William L. Mengeling, Kelly M. Lager, Ann C. Vorwald
-
Patent number: 5928649Abstract: A method of reversing or preventing immunosuppression or antigenic interference associated with combination vaccines in mammals, is disclosed. Cytokines, or cytokine inducer, are administered in conjunction with the combination vaccine. The cytokine or cytokine inducer can be administered concurrently with or subsequently to the vaccine, and can be recombinantly produced or isolated from cell culture.Type: GrantFiled: May 31, 1995Date of Patent: July 27, 1999Assignee: American Cyanamid CompanyInventors: Michael Joseph Daley, Phillip Wayne Hayes
-
Patent number: 5925359Abstract: The present invention is concerned with European strains of the Porcine Reproductive Respiratory Syndrome (PRRS) virus, having as a unique feature that they are non-infectious to macrophages, and to methods for the production of such strains. The invention also provides vaccines for the protection of pigs against PRRS, based on these strains, as well as methods for the production of such vaccines.Type: GrantFiled: October 9, 1997Date of Patent: July 20, 1999Assignee: Akzo Nobel, N.V.Inventors: Petrus Alphonsus Maria Van Woensel, Jean Guillaume Joseph Demaret
-
Patent number: 5888513Abstract: Recombinant proteins of the causative virus of porcine reproductive and respiratory syndrome (PRRS), corresponding to ORFs 2 to 7 of the PRRSV Spanish isolate (PRRS-Olot), have been produced in baculovirus expression system using Sf9 cell cultures as a permissive host. These recombinant proteins are suitable for the formulation of vaccines capable of efficaciously protecting porcine livestock from PRRS and for the preparation of diagnostic kits adequate for detection of anti-PRRSV antibodies as well as of PRRSV in a pig biological sample. This invention is of interest to Veterinary Medicine.Type: GrantFiled: April 8, 1996Date of Patent: March 30, 1999Assignee: Cyanamid Iberica, S.A.Inventors: Juan Plana Duran, Jose Ignacio Casal Alvarez, Isabel Climent Sanchez
-
Patent number: 5866117Abstract: A sustainable cell line of a Marek's disease herpesvirus (MDV) infected chicken cell line derived from chick embryo cells which are chicken helper factor (Chf) negative and which have been treated with N-methyl-N-nitro-N-nitrosoguansidine (MNNG) and then converted with the MDV which is able to infect avians in vivo. The cell line is useful for vaccine production and for determining the characteristics of the MDV under various conditions.Type: GrantFiled: August 19, 1997Date of Patent: February 2, 1999Assignee: Board of Trustees operating Michigan State UniversityInventors: Paul M. Coussens, Amin Abujoub
-
Patent number: 5763409Abstract: A stable, freeze-dried, and pharmaceutically acceptable formulation includes a protein, a buffer, alanine, and mannitol, at a mass ratio of mannitol/alanine being 0.1-1, wherein the formulation being useful in an assay kit.Type: GrantFiled: May 2, 1995Date of Patent: June 9, 1998Assignee: SanofiInventors: Alain Bayol, Thierry Breul, Patrice Dupin, Philippe Faure
-
Patent number: 5695766Abstract: The present invention provides a vaccine which protects pigs from a virus and/or an infectious agent causing a porcine respiratory and reproductive disease, a method of protecting a pig from a disease caused by a virus and/or an infectious agent which causes a respiratory and reproductive disease, a method of producing a vaccine against a virus and/or an infectious agent causing a porcine reproductive and respiratory disease, and a biologically pure sample of a virus and/or infectious agent associated with a porcine respiratory and reproductive disease, particularly the Iowa strain of porcine reproductive and respiratory syndrome virus (PRRSV), and an isolated polynucleotide which is at least 90% homologous with a polynucleotide obtained from the genome of a virus and/or infectious agent which causes a porcine respiratory and reproductive disease.Type: GrantFiled: October 5, 1993Date of Patent: December 9, 1997Assignees: Iowa State University Research Foundation, Solvay Animal Health, Inc.Inventors: Prem S. Paul, Patrick G. Halbur, Xiang-Jin Meng, Young S. Lyoo, Melissa Anne Lum
-
Patent number: 5620691Abstract: Composition of matter comprising the causative agent of Mystery Swine Disease, Lelystad Agent, in a live, attenuated, dead, or recombinant form, or a part or component of it. Vaccine compositions and diagnostic kits based thereon. Recombinant nucleic acid comprising a Lelystad Agent-specific nucleotide sequence. Peptides comprising a Lelystad Agent-specific amino acid sequence. Lelystad Agent-specific antibodies.Type: GrantFiled: November 26, 1993Date of Patent: April 15, 1997Assignee: Stichting Centraal Diergeneeskundig InstituutInventors: Gert Wensvoort, Catharinus Terpstra, Joannes M. A. Pol
-
Patent number: 5587164Abstract: A process for growing a PRRSV in a tissue culture which is susceptible to infection to replicate the virus to an amount sufficient to protect animals against PRRS or be used in diagnosing PRRS or identifying the molecular structure of PRRSV for development of recombinant products, comprising inoculating the virus onto the tissue culture and harvesting the replicated virus.Type: GrantFiled: December 6, 1994Date of Patent: December 24, 1996Assignees: Bayer Corporation, Iowa State University Research Foundation, Inc.Inventors: Thomas Sanderson, Michael J. McGinley, Jeffrey J. Zimmerman, Howard T. Hill, Michael C. Meetz, Eugene C. Pirtle, Sabrina L. Swenson, George P. Shibley
-
Patent number: 5580564Abstract: The invention relates to a microorganism having a modified cell, tissue or host tropism whereby at least one gene of the microorganism, preferably an essential gene, is brought under the control of a nucleotide sequence specific for the cell, the tissue or the host. The specific nucleotide sequence can be a promoter sequence and/or enhancer sequence, which can be inducible. The invention is also directed at the use of such a recombinant microorganism for the provision of protection against the corresponding natural microorganism.Type: GrantFiled: December 22, 1994Date of Patent: December 3, 1996Assignee: Akzo Nobel N.V.Inventors: Koenraad L. Glazenburg, Robertus J. M. Moormann
-
Patent number: 5419907Abstract: The present invention provides a biologically pure culture of a novel pathogenic porcine respiratory coronavirus (PRCV) and a vaccine derived therefrom effective against PRCV infection and transmissible gastroenteritis virus (TGEV) infection.Type: GrantFiled: November 10, 1992Date of Patent: May 30, 1995Assignee: Iowa State University Research Foundation, Inc.Inventors: Prem S. Paul, Eric M. Vaughn, Patrick G. Halbur
-
Patent number: 5352596Abstract: An attenuated pseudorabies virus (PRV) having a reduced ability to reactivate from latency is produced by introducing (1) a genomic modification in the early protein 0 (EP0) gene whereby said virus is characterized by the inability to express the early protein 0; or (2) a genomic modification in the large latency transcript (LLT) gene whereby said virus is characterized by disruption of the synthesis of said large latency transcript; or (3) the genomic modifications described in both (1) and (2). The attenuated virus is useful in a vaccine for psuedorabies-susceptible animals, particularly swine. Swine vaccinated with a deletion mutant in the EP0/LLT overlap region displayed reduced virus shedding and fewer clinical signs than animals inoculated with a wild type virus. The deletion mutant-vaccinated swine also harbored less PRV DNA in the nervous tissue and showed reduced ability to reactivate the virus.Type: GrantFiled: September 11, 1992Date of Patent: October 4, 1994Assignee: The United States of America as represented by the Secretary of AgricultureInventors: Andrew K. Cheung, Ronald D. Wesley